ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.704,45
-0,08%
S&P 500
5.333,47
0,80%
US Dollar vs BRL
5,2925
0,06%
Bitcoin
71.543,44
1,30%
Brent Oil
78,185
1,39%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Seres Therapeutics Inc (MCRB)

  7. Seres Therapeutics Inc (MCRB) Notícias

MCRB

Seres Therapeutics (MCRB)

Seres Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MCRB
DataHoraFonteTítuloCódigoCompanhia
17/05/202421:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
08/05/202411:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MCRBSeres Therapeutics Inc
08/05/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
08/05/202408:00Business WireSeres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
06/05/202417:01Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
06/05/202410:30Business WireSeres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024NASDAQ:MCRBSeres Therapeutics Inc
09/04/202408:00Business WireSeres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTNASDAQ:MCRBSeres Therapeutics Inc
05/03/202412:18Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MCRBSeres Therapeutics Inc
05/03/202412:13Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MCRBSeres Therapeutics Inc
05/03/202409:00Business WireSeres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
05/03/202408:05IH Market NewsU.S. Futures Dip, Crude Oil FluctuatesNASDAQ:MCRBSeres Therapeutics Inc
28/02/202409:00Business WireSeres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024NASDAQ:MCRBSeres Therapeutics Inc
27/02/202409:00Business WireSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
26/02/202409:00Business WireSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzNASDAQ:MCRBSeres Therapeutics Inc
23/02/202418:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MCRBSeres Therapeutics Inc
09/01/202410:10Dow Jones NewsSeres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection TreatmentNASDAQ:MCRBSeres Therapeutics Inc
09/01/202409:00Business WireSeres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155NASDAQ:MCRBSeres Therapeutics Inc
04/01/202418:00Business WireSeres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
07/12/202321:46Business WireSeres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023NASDAQ:MCRBSeres Therapeutics Inc
28/11/202311:18Business WireSeres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ETNASDAQ:MCRBSeres Therapeutics Inc
27/11/202321:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:MCRBSeres Therapeutics Inc
21/11/202308:00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:MCRBSeres Therapeutics Inc
02/11/202308:00Business WireSeres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 MillionNASDAQ:MCRBSeres Therapeutics Inc
01/11/202311:30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:MCRBSeres Therapeutics Inc
30/10/202318:30Business WireSeres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. ESTNASDAQ:MCRBSeres Therapeutics Inc
12/10/202308:00Business Wire Seres Therapeutics to Highlight VOWST™ Data at IDWeekNASDAQ:MCRBSeres Therapeutics Inc
11/09/202307:30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:MCRBSeres Therapeutics Inc
07/09/202311:00Business WireSeres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
29/08/202310:00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:MCRBSeres Therapeutics Inc
16/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MCRBSeres Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MCRB

Seu Histórico Recente

COIN
QABTC
Quantum Assets Token
LSE
OEM
OEM Plc
LSE
JRP
JRP Group
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados